Inovio to Plunge Ahead of Earnings Report

Inovio to Plunge Ahead of Earnings Report

2022-12-15 • Updated

About the company

Inovio Pharmaceuticals Inc (INO) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines to treat and prevent various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology.

Recent history

When the pandemic roiled America in 2020, COVID stocks, including Inovio, gained momentum. Robinhood named Inovio as one of the top 10 most traded stocks on its platform in April 2020, putting Inovio in line with Microsoft (MSFT), Disney (DIS), and Tesla (TSLA). However, the company hasn't been successful in developing a vaccine.

Initially, Inovio announced plans to develop COVID-19 vaccines targeting the recently discovered Omicron variant, which boosted the stock. However, in March 2022, Inovio stated that it paused the development of its phase 3 INO-4800 trial.

The company announced an update of the strategy on the Q1, 2022 earnings call and its more recent CEO presentation at Jefferies 2022 Global Healthcare Conference in June 2022.

CEO Shea described the situation as follows:

"As the COVID-19 pandemic evolves towards the endemic phase, the need for booster vaccines to protect against severe illness and death represents a growing and strategic opportunity. In light of this, we now believe that Inovio can have the greatest impact and serve the most pressing public health needs by focusing on the COVID vaccine in our heterologous booster strategy".

Upcoming events

Inovio Pharmaceuticals Inc will release the Q2 2022 financial results on August 9, after the market close (23:30 GMT+3). Following the release, INOVIO will host a live conference call to discuss the financial statement and provide a general business update.

What to expect? 

The recent history shows the stock usually falls ahead of earnings reports on expectations of worse-than-expected results. Moreover, after the two latest reports (May 10, 2022, and March 01, 2022), the price opened lower with a gap and returned to growth the next day. 

In Q2 2022, the company didn't succeed in drug development, and actual financial results will likely underperform the expectations. Therefore, FBS analysts believe the stock might plunge ahead of the report.  

Technical analysis

INO, H4 chart


Resistance: $2.27, $2.35

Support: $1.94, $1.83, $1.73

On Friday, July 29, the stock dropped out of the descending channel despite the growth of the US stock indices, highlighting its weakness ahead of the earnings report. 

If the price doesn't return inside the channel on Monday, the bears will be able to bring it down to the $1.73, 61.8 Fibonacci level. Moreover, the breakout of $1.73 opens the way to $1.40. 

Do you want to get updates Live? Subscribe to the @FBSAnalytics Telegram Channel where I post more daily trade ideas!



Stocks To Watch For March
Stocks To Watch For March

During his program on CNBC on February 28, Jim Cramer expressed frustration with the impact of earnings reports on market behavior, noting how they often prompt rash decisions by average investors. He criticized the short-term focus and lack of attention to nuance in news coverage of earnings. Cramer cited examples of Home Depot and Lowe's, highlighting how investors reacted hastily to headline news without considering the broader context provided in earnings calls.

Nasdaq, S&P 500 Reach Record Highs
Nasdaq, S&P 500 Reach Record Highs

After creating record highs, Wall Street's main indexes opened on Wednesday and began to edge lower, reflecting cautious sentiment among investors. They're eagerly awaiting crucial inflation data that could impact the U.S. Federal Reserve's interest rate decisions. The upcoming release of the personal consumption expenditures (PCE) price index is expected...

Stock Market Rally. How Far Can It Go?
Stock Market Rally. How Far Can It Go?

Global equities on Wall Street experienced a mixed session following the Thanksgiving holiday, heading for the most significant one-month rally since November 2020. MSCI's global shares index slightly eased but was still on track for an 8.5% monthly gain, fueled by growing investor confidence that U.S. interest rates...

Latest news

USD: Powell Speaks on Cutting Interest Rates
USD: Powell Speaks on Cutting Interest Rates

Jerome H. Powell, the Federal Reserve chair, stated that the central bank can afford to be patient in deciding when to cut interest rates, citing easing inflation and stable economic growth. Powell emphasized the Fed's independence from political influences, particularly relevant as the election season nears. The Fed had raised interest rates to 5.3 ...

WTT: Currency Pairs To Trade In April
WTT: Currency Pairs To Trade In April

Hello again my friends, it’s time for another episode of “What to Trade,” this time, for the month of April. As usual, I present to you some of my most anticipated trade ideas for the month of April, according to my technical analysis style. I therefore encourage you to do your due diligence, as always, and manage your risks appropriately.

Deposit with your local payment systems

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.


A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera